Chief Transformation Officer · GeneDx Holdings Corp. (WGS)

Kareem Saad

A named executive officer of GeneDx in every fiscal year CompBrief holds from FY2022 to FY2023. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$1,188,018

Salary $375,000Stock awards $771,658

FY2022: $2,067,029

3rd of 4 named executive officers at GeneDx by FY2023 total.

4 named officers on file for GeneDx, FY2023

Kareem Saad’s pay file — $29

  • 2 fiscal years of pay, line by line
  • WGS’s disclosed peer group of 17 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how GeneDx’s whole pay program stands against its peers

  • GeneDx’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on WGS→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 29, 2024 (DEF 14A).

Free

Get Kareem Saad’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Kareem Saad compensation by year

GeneDx Summary Compensation Table · all 2 fiscal years held
In US dollars, as GeneDx reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2022FY2023
Salary$375,000$375,000
Bonus$34,000$0
Stock awards$849,833$771,658
Option awards$762,927$0
Non-equity incentive$0$0
Pension and deferred compensation$0$0
All other$45,269$41,360
Total$2,067,029$1,188,018

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: GeneDx Holdings Corp. DEF 14A filed April 29, 2024, accession 0001818331-24-000025, and prior-year filings. Open the filing on EDGAR.

How this page was built: the GeneDx Holdings Corp. filed document, accession 0001818331-24-000025. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2024.

$2.1M
$1.2M
FY22
FY23
SalaryBonusStock awardsOption awardsAll other

GeneDx’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Katherine StuelandChief Executive Officer$3,575,335
Kevin FeeleyChief Financial Officer$1,574,227
Kareem Saad · this pageChief Transformation Officer$1,188,018
Jason RyanChairman of the Board (4)$992,464

The full GeneDx compensation record

free company brief

This page is one person within GeneDx's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the GeneDx proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are GeneDx's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Kareem Saad's compensation dossier · One-time report. No refunds.